XRAY Q3 2025: U.S. Sales Drop 22% as Bold Turnaround Plan Targets 2026 Recovery
Dentsply Sirona faces a pivotal inflection as U.S. sales contraction and leadership transition sharpen the urgency behind CEO Dan Scavilla’s aggressive “Return to Growth” action plan. Management is shifting capital into R&D and commercial execution, betting that deeper customer focus and operational overhaul will reverse multi-year stagnation. Investors are watching for tangible progress in U.S. stabilization, margin recovery, and proof that this turnaround is more than rhetoric.
Summary
- U.S. Market Share Under Pressure: Deep sales declines drive urgent commercial restructuring and renewed dealer partnerships.
- Leadership Reset Accelerates Change: CFO exit and new commercial leadership reflect a mandate for execution and accountability.
- Investment Shift Signals 2026 Focus: Capital is being redeployed into R&D and sales force expansion to reignite growth next year.
Performance Analysis
Q3 revealed a stark divergence between geographies, with U.S. sales down 22.2% and persistent weakness across essential dental solutions, CAD/CAM, imaging, and implants. Even after normalizing for prior year one-time dealer pre-buys and the “bite impact,” the U.S. business remains down nearly 10%. This underscores structural issues in channel strategy, execution, and customer engagement that have not yet been solved by previous turnaround efforts.
Europe emerged as a relative bright spot, with reported sales up 9.9% (2.6% constant currency), driven by connected technology and lab strength in key markets like the UK, France, Italy, and Spain. The rest of world performance was flat, with Australia and India offsetting softness in Japan. WellSpec, the healthcare business outside core dental, posted 9.3% growth globally and an outsized 87.3% in Rest of World, though from a small base.
- Tariff and Mix Headwinds: Gross profit was pressured by tariffs and adverse sales mix, with half of the EPS decline attributed to these factors.
- OPEX Discipline Offsets Margin Drag: Reduced operating expense partially mitigated profit headwinds, but the company is now intentionally increasing OpEx to fund growth initiatives.
- Non-Cash Impairments Reflect Lower Outlook: A $263 million goodwill and intangibles charge signals lower projected volumes in equipment, implants, and prosthetics, especially in the U.S.
Cash flow from operations was $79 million, and $32 million was returned to shareholders via dividends. The company is prioritizing cash redeployment toward R&D and commercial investments, with the dividend’s future under review as part of a broader capital allocation reset.
Executive Commentary
"This plan requires us to go deeper, move faster, and be bolder to reshape and improve the customer experience. I believe the potential for Dentsply Sirona has never been greater, and we have at our fingertips what we need to achieve this."
Dan Scavilla, President and Chief Executive Officer
"Matt Garth, our Chief Financial Officer, has departed the company. This action is not the result of any dispute, disagreement, or financial reporting matter. Matt was not the right fit for me and where I plan to take the enterprise in the finance organization."
Dan Scavilla, President and Chief Executive Officer
Strategic Positioning
1. U.S. Commercial Turnaround as Top Priority
Reversing U.S. sales decline is the centerpiece of the new strategy. The company is restructuring commercial teams, re-engaging with dealer partners (notably Schein and Patterson), and investing in sales force expansion and training. A multi-channel approach aims to balance direct and dealer sales, with a renewed focus on dental service organizations (DSOs, large dental practice operators) and clinical education. The new Chief Commercial Officer, Aldo Dente, brings turnaround experience from Johnson & Johnson and is charged with instilling discipline and market focus.
2. R&D and Innovation Investment Ramp
R&D spend is being pulled forward into Q4 and earmarked for acceleration in 2026, with a target range of 6-7% of sales over time. CEO Scavilla is prioritizing efficiency and risk mitigation within R&D, ensuring investments translate into marketable product launches and clinical differentiation—especially in connected technology and single-visit care.
3. Organizational and Operational Overhaul
Leadership transitions and organizational redesign are underway. The CFO departure and interim oversight by a board member highlight a focus on financial discipline and data-driven management. The creation of a Transformation Office, led by a new Chief Transformation Officer, is intended to drive cross-functional improvements, enterprise AI, automation, and digital transformation. Support functions will be streamlined, with SAP ERP rollout and consolidation of legal entities to unlock capital for reinvestment.
4. WellSpec Retention and Portfolio Rationalization
After evaluating strategic alternatives, management will retain WellSpec, the non-core healthcare business, citing its cash generation and growth optionality. This move aims to provide stability and incremental capital for broader transformation efforts, while previous footprint consolidation and SKU rationalization continue to free up resources for commercial investment.
5. Global Expansion and Regional Playbooks
European execution is being held up as a model, with local leadership credited for cross-functional resource alignment and growth. The Asia-Pacific strategy is under review, with new go-to-market models planned for Japan and refinements in China. As U.S. momentum returns, capital allocation will shift to EMEA and APAC to drive global growth.
Key Considerations
This quarter marks a clear inflection between rhetoric and action for Dentsply Sirona. Execution risk is high, but so is the potential for a meaningful turnaround if operational discipline and commercial focus are sustained.
Key Considerations:
- Dealer and DSO Re-engagement: Success hinges on rebuilding trust and channel partnerships in the U.S., which have been a persistent Achilles’ heel.
- Sales Force Effectiveness: Field rep hiring, training, and retention are explicit KPIs, with clinical education and university presence seen as levers for long-term share gains.
- R&D ROI Scrutiny: New investments must yield differentiated products and faster innovation cycles to regain lost ground, especially in implants and CAD/CAM.
- Operational Streamlining: SAP ERP implementation and support function consolidation are expected to unlock capital, but execution risk remains if integration lags.
- Leadership Stability and Accountability: The CFO transition and new commercial leadership are double-edged, offering both fresh perspective and potential for disruption if alignment is not achieved quickly.
Risks
Execution risk is elevated, with U.S. channel relationships, sales force ramp, and R&D efficiency all requiring rapid improvement. Tariff volatility and adverse sales mix could continue to pressure margins, while leadership turnover adds uncertainty. The company’s ability to deliver sequential improvement in 2026 is not yet proven, and the risk of further impairments or missed targets remains if operational changes do not materialize as planned.
Forward Outlook
For Q4 2025, Dentsply Sirona guided to:
- Net sales in the range of $3.6 to $3.7 billion for the full year
- Constant currency sales expected down 5% to 4% year over year
- Adjusted EPS of approximately $1.60
Management emphasized:
- Targeted investments in R&D and commercial execution will be front-loaded in Q4 to set the stage for 2026 growth
- Sequential improvements are expected in 2026, but management is not yet ready to provide specific quarterly cadence
Takeaways
XRAY’s Q3 call signals a decisive break from incrementalism, with leadership betting on a bold, multi-pronged transformation to reverse U.S. share loss and reignite growth. The next 12 months are critical for restoring credibility and demonstrating that capital redeployment and operational overhaul can yield tangible results.
- U.S. Commercial Execution: The success of the turnaround hinges on quickly stabilizing and growing the U.S. business through channel repair, sales force expansion, and customer-centricity.
- R&D and Innovation Payoff: Investors should watch for accelerated product launches and clinical adoption as a result of increased R&D investment and tighter portfolio focus.
- 2026 Sequential Improvement: The market will demand evidence of quarterly progress in margins, sales, and share gains, not just strategic intent.
Conclusion
Dentsply Sirona is at a strategic crossroads, with deep U.S. weakness and organizational change driving an aggressive turnaround plan. Execution over the next year will determine whether this is another false dawn or the start of sustained recovery and market leadership.
Industry Read-Through
XRAY’s struggles and strategy reset reflect broader challenges in dental and medtech distribution, where channel relationships, sales force effectiveness, and innovation cycles are under pressure. Competitors with strong dealer and DSO engagement, nimble commercial teams, and clear R&D ROI are likely to outperform. The renewed focus on operational efficiency and digital transformation is a signal for peers to accelerate automation and customer-centricity, while the retention of non-core assets like WellSpec highlights the importance of cash flow diversification in uncertain markets.